NCT07046156

Treatment of Overactive Bladder With Anticholinergic Agents

Evaluation of Anticholinergic Treatment Response and Predictive Factors in Pediatric Overactive Bladder

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital · Academic / Other
• Sex: All
• Age: 5 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy and adverse effect incidence of three different anticholinergics (oxybutinin, propiverine, and tolterodine) that are used in children with overactive bladder.

Detailed description

A total of approximately 150 patients with overactive bladder will be evaluated retrospectively. Clinical and demographic data and voiding diaries of these patients will be evaluated. For this purpose, patients will be divided into mainly three groups according to the anticholinergic agent used.

Conditions

• Overactive Bladder

Interventions

Type	Name	Description
DRUG	Oxybutynin Cl	Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder
DRUG	propiverine	Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder
DRUG	Tolterodine	Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder

Timeline

• Start date: 2022-09-01
• Primary completion: 2025-06-30
• Completion: 2026-06-01
• First posted: 2025-07-01
• Last updated: 2025-07-01

Locations

1 site across 1 country: Turkey (Türkiye)

Regulatory

• FDA-regulated drug study